21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Distinctive genotypes in infants with T‐cell acute lymphoblastic leukaemia

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Infant T‐cell acute lymphoblastic leukaemia ( iTALL) is a very rare and poorly defined entity with a poor prognosis. We assembled a unique series of 13 infants with T‐ ALL, which allowed us to identify genotypic abnormalities and to investigate prenatal origins. Matched samples (diagnosis/remission) were analysed by single nucleotide polymorphism‐array to identify genomic losses and gains. In three cases, we identified a recurrent somatic deletion on chromosome 3. These losses result in the complete deletion of MLF1 and have not previously been described in T‐ ALL. We observed two cases with an 11p13 deletion ( LMO2 ‐related), one of which also harboured a deletion of RB1 . Another case presented a large 11q14·1‐11q23·2 deletion that included ATM and only five patients (38%) showed deletions of CDKN2A/B . Four cases showed NOTCH1 mutations; in one case FBXW7 was the sole mutation and three cases showed alterations in PTEN . KMT2A rearrangements ( KMT2A‐r ) were detected in three out of 13 cases. For three patients, mutations and copy number alterations (including deletion of PTEN ) could be backtracked to birth using neonatal blood spot DNA, demonstrating an in utero origin. Overall, our data indicates that iTALL has a diverse but distinctive profile of genotypic abnormalities when compared to T‐ ALL in older children and adults.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: found

          Hallmarks of Cancer: The Next Generation

          The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

            In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 multiplex PCR tubes: three VH-JH, two DH-JH, two Ig kappa (IGK), one Ig lambda (IGL), three TCR beta (TCRB), two TCR gamma (TCRG), one TCR delta (TCRD), three BCL1-Ig heavy chain (IGH), and one BCL2-IGH. The PCR products of Ig/TCR genes can be analyzed for clonality assessment by heteroduplex analysis or GeneScanning. The detection rate of clonal rearrangements using the BIOMED-2 primer sets is unprecedentedly high. This is mainly based on the complementarity of the various BIOMED-2 tubes. In particular, combined application of IGH (VH-JH and DH-JH) and IGK tubes can detect virtually all clonal B-cell proliferations, even in B-cell malignancies with high levels of somatic mutations. The contribution of IGL gene rearrangements seems limited. Combined usage of the TCRB and TCRG tubes detects virtually all clonal T-cell populations, whereas the TCRD tube has added value in case of TCRgammadelta(+) T-cell proliferations. The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

              Very rare cases of human T cell acute lymphoblastic leukemia (T-ALL) harbor chromosomal translocations that involve NOTCH1, a gene encoding a transmembrane receptor that regulates normal T cell development. Here, we report that more than 50% of human T-ALLs, including tumors from all major molecular oncogenic subtypes, have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1. These findings greatly expand the role of activated NOTCH1 in the molecular pathogenesis of human T-ALL and provide a strong rationale for targeted therapies that interfere with NOTCH signaling.
                Bookmark

                Author and article information

                Journal
                Br J Haematol
                Br. J. Haematol
                10.1111/(ISSN)1365-2141
                BJH
                British Journal of Haematology
                John Wiley and Sons Inc. (Hoboken )
                0007-1048
                1365-2141
                24 July 2015
                November 2015
                : 171
                : 4 ( doiID: 10.1111/bjh.2015.171.issue-4 )
                : 574-584
                Affiliations
                [ 1 ] Centre for Evolution and CancerThe Institute of Cancer Research LondonUK
                [ 2 ] Paediatric Haematology‐Oncology Program, Research CentreInstituto Nacional de Câncer Rio de JaneiroBrazil
                [ 3 ] Centre for Biological SciencesUniversity of Southampton SouthamptonUK
                [ 4 ] Paediatric Malignancy Cytogenetics UnitInstitute of Child Health & Great Ormond Street Hospital LondonUK
                [ 5 ] Department of Genetics Robert Debré HospitalAPHP ParisFrance
                [ 6 ] Haematology Laboratory Saint‐Louis Louis HospitalAPHP ParisFrance
                Author notes
                [*] [* ] Correspondence: Dr Anthony M. Ford and Dr Marcela B. Mansur, Centre for Evolution and Cancer, The Institute of Cancer Research (ICR) ‐ London, Brookes Lawley Building, 15 Cotswold Road, Sutton ‐ Surrey SM2 5NG, UK

                E‐mails: tony.ford@ 123456icr.ac.uk and mmansur@ 123456inca.gov.br

                Article
                BJH13613
                10.1111/bjh.13613
                4737125
                26205622
                e1a8a8e3-6e4b-4448-98ac-20a6c813a02c
                © 2015 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 April 2015
                : 25 June 2015
                Page count
                Pages: 11
                Funding
                Funded by: European Hematology Association
                Funded by: Lady Tata Memorial Trust
                Funded by: INCA
                Funded by: CNPq
                Funded by: FAPERJ
                Funded by: Kay Kendall Leukaemia Fund
                Funded by: Leukaemia & Lymphoma Research
                Funded by: Institute of Cancer Research
                Categories
                Research Paper
                Paediatrics
                Custom metadata
                2.0
                bjh13613
                November 2015
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.5 mode:remove_FC converted:26.01.2016

                Hematology
                infant,t‐cell acute lymphoblastic leukaemia,genomic profile,cnas and in utero origin

                Comments

                Comment on this article